Advertisement
AXON vs TECH
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Bio-Techne (TECH) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON), with a $32.4 billion market capitalization, significantly outpaces Bio-Techne (TECH)'s $8.6 billion in scale across the Industrials and Healthcare sectors, respectively.
- AXON has delivered stronger year-to-date gains of 29.16%, compared to TECH's 6.32%.
- Both stocks face upcoming earnings reports on May 6, 2026, potentially influencing short-term momentum.
- AXON guides for 27-30% revenue growth in 2026, driven by AI initiatives, while TECH anticipates modest expansion.
- Recent weeks show AXON pulling back amid valuation concerns, contrasting TECH's relative stability.
- Divergent sectors expose AXON to public safety tech trends and TECH to biotechnology dynamics.
Introduction
Axon Enterprise (AXON) and Bio-Techne (TECH) represent distinct opportunities in the Industrials and Healthcare sectors, respectively. This comparison evaluates their business models, recent market performance, and growth trajectories amid evolving economic conditions. Traders seeking momentum plays may eye AXON's AI-driven innovations, while investors favoring stability might assess TECH's biotechnology tools. With both set for earnings in early May 2026, the analysis highlights relative strengths for portfolio diversification or sector rotation strategies.
AXON Overview and Recent Performance
Axon Enterprise, Inc. (AXON) develops public safety technologies, including body cameras, tasers, and cloud-based software solutions. Operating in the Industrials sector's Aerospace & Defense industry, the company holds a market cap of $32.4 billion and trades at approximately $402 per share. In recent market activity, AXON experienced a pullback from March highs near $450, reflecting concerns over elevated valuation (P/E ratio of 263) and debt levels, despite year-to-date gains of 29%. Sentiment has been buoyed by strong Q4 results, with 40% software revenue growth, and anticipation for 27-30% full-year expansion fueled by AI-powered 911 platforms. Upcoming Q1 earnings on May 6 could catalyze further movement, though high P/E (price-to-earnings ratio) signals growth premium risks.
TECH Overview and Recent Performance
Bio-Techne Corporation (TECH) provides biotechnology reagents, instruments, and diagnostics for research and clinical applications within the Healthcare sector's Biotechnology industry. Its market cap stands at $8.6 billion, with shares around $55. Recent weeks have seen relative price stability near $52-55, supported by year-to-date returns of 6.3%, amid a 52-week range of $46-$72. Key developments include a streamlined brand architecture to enhance customer workflows and a rating upgrade to Buy, though organic growth scrutiny persists with a P/E ratio of 104 and modest EPS (earnings per share) of $0.53. Q3 fiscal 2026 earnings on May 6, projecting $320 million revenue, may influence sentiment in a competitive biotech landscape.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 performers from over 350 AI trading bots that analyze thousands of tickers across diverse strategies, timeframes, and styles like short-term scalping or sector-themed trades. These bots shine in volatile conditions, boasting annualized returns from 24% to 163%, win rates of 51-88%, profit factors up to 11.7, and average trade durations of 1-6 days. Selected via AI for relevance to hot sectors such as semiconductors and data centers, they offer copy-trading signals with risk-managed virtual agents. Explore these high-performing options to align with current market dynamics.
Head-to-Head Comparison
AXON's hardware-software ecosystem targets public safety with recurring SaaS (software-as-a-service) revenue, contrasting TECH's focus on biotech consumables and instruments for steady but lower-margin research demand. Growth drivers differ: AXON leverages AI catalysts for 27-30% expansion, while TECH faces organic hurdles despite brand enhancements. Recent momentum favors AXON's YTD outperformance, though its volatility and debt pose risks versus TECH's stability. AXON benefits from Industrials tailwinds, while TECH navigates Healthcare regulatory sensitivities. Valuation trade-offs highlight AXON's premium for growth against TECH's relative affordability, shaping sentiment divergence.
Tickeron AI Verdict
Tickeron's AI currently leans toward AXON based on superior trend consistency, robust growth guidance, and AI catalyst momentum relative to TECH's steadier but subdued positioning. Observable factors like stronger YTD returns and software expansion suggest higher probabilistic upside, though both warrant monitoring post-earnings for stability confirmation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Buy and TECH is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileTECH’s FA Score has 2 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- TECH’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 5 TA indicator(s) are bullish while TECH’s TA Score has 5 bullish TA indicator(s).
- AXON’s TA Score: 5 bullish, 4 bearish.
- TECH’s TA Score: 5 bullish, 5 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а +8.33% price change this week, while TECH (@Biotechnology) price change was +0.60% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -8.63%. For the same industry, the average monthly price growth was +4.97%, and the average quarterly price growth was +23.70%.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -7.98%, and the average quarterly price growth was -1.75%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
TECH is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Aerospace & Defense (-8.63% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-7.86% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | TECH | AXON / TECH | |
| Capitalization | 41.4B | 8.33B | 497% |
| EBITDA | 320M | 257M | 125% |
| Gain YTD | -14.405 | -11.314 | 127% |
| P/E Ratio | 196.02 | 74.27 | 264% |
| Revenue | 2.98B | 1.21B | 246% |
| Total Cash | 737M | N/A | - |
| Total Debt | 1.83B | 351M | 521% |
AXON | TECH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 31 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 58 | 100 | |
SMR RATING 1..100 | 82 | 85 | |
PRICE GROWTH RATING 1..100 | 56 | 61 | |
P/E GROWTH RATING 1..100 | 41 | 30 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TECH's Valuation (2) in the Biotechnology industry is significantly better than the same rating for AXON (80). This means that TECH’s stock grew significantly faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (58) in the Biotechnology industry is somewhat better than the same rating for TECH (100). This means that AXON’s stock grew somewhat faster than TECH’s over the last 12 months.
AXON's SMR Rating (82) in the Biotechnology industry is in the same range as TECH (85). This means that AXON’s stock grew similarly to TECH’s over the last 12 months.
AXON's Price Growth Rating (56) in the Biotechnology industry is in the same range as TECH (61). This means that AXON’s stock grew similarly to TECH’s over the last 12 months.
TECH's P/E Growth Rating (30) in the Biotechnology industry is in the same range as AXON (41). This means that TECH’s stock grew similarly to AXON’s over the last 12 months.
| AXON | TECH | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 63% | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 70% |
| MACD ODDS (%) | N/A | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 67% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 69% |
| Advances ODDS (%) | 4 days ago 74% | 2 days ago 71% |
| Declines ODDS (%) | 11 days ago 69% | 4 days ago 74% |
| BollingerBands ODDS (%) | 2 days ago 57% | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 72% | 2 days ago 71% |
Advertisement
AXON and
Correlation & Price change
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | -5.28% | ||
| TECH - AXON | 61% Loosely correlated | -2.24% | ||
| VCYT - AXON | 58% Loosely correlated | -2.40% | ||
| BEAM - AXON | 57% Loosely correlated | -10.48% | ||
| SEER - AXON | 56% Loosely correlated | -3.51% | ||
| ADPT - AXON | 56% Loosely correlated | -6.55% | ||
More | ||||